Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement

This study has been completed.
Sponsor:
Information provided by:
Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier:
NCT01319799
First received: March 21, 2011
Last updated: July 19, 2011
Last verified: November 2010
  Purpose

The use of MRI have shown that the incidence of postoperative cerebral lesions due to cerebral embolization is high (1). Nonetheless the extent of postoperative neurological dysfunction is only a fraction of the actual amount of new postoperative changes detected on MRI. Transcranial Doppler (TCD) has shown the occurrence of extensive microembolic signals in intracerebral arteries during open heart procedures (2). The clinical significance of cerebral microemboli is not clear (3-5). The use of serological markers to assess cerebral injury after open cardiac surgery is difficult to interpret. The levels of markers seems to be contaminated from extracerebral sources (6). In order assess the release of markers of neuronal damage after open aortic valve surgery the investigators intend to examine the levels of S-100B, NSE and Tau in cerebrospinal fluid (CSF) by comparing the levels preoperative with the levels one day after surgery. Furthermore the investigators will determine the total amount of cerebral microembolic signals during the surgical procedure by means of TCD. The investigators will statistically test if there is any correlation between the increase in cerebrospinal fluid levels of S-100B,NSE and Tau and the cerebral embolic load.


Condition Intervention
Aortic Stenosis
Other: Open heart surgery

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve

Resource links provided by NLM:


Further study details as provided by Sahlgrenska University Hospital, Sweden:

Primary Outcome Measures:
  • Transcranial Doppler(TCD) microembolic signals during surgical aortic valve replacement surgery [ Time Frame: (day 1) TCD will be performed from start of surgery till end of surgery-exact time cannot be stated in advance ] [ Designated as safety issue: Yes ]
    Transcranial Doppler measurement of microembolic signals will be measured during the surgical procedure.The exact time is not possible to estimate in advance, but usually approximates 2 hrs in duration


Secondary Outcome Measures:
  • Cerebrospinal fluid(CSF) levels of S-100B,NSE and Tau Time Frame: Description: Differences in preoperative vs postoperative CSF levels of S-100B/NSE/Tau Cerebrospinal fluid(CSF) levels of S-100B,NSE and Tau [ Time Frame: 24 Hours after Surgery ] [ Designated as safety issue: Yes ]
    Differences in preoperative vs postoperative CSF levels of S-100B/NSE/Tau


Biospecimen Retention:   Samples Without DNA

Cerebrospinal fluid levels of S100B, NSE , Tau and albumin detected by elctrochemoluminescence immunoassay.


Enrollment: 10
Study Start Date: November 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Surgical aortic valve replacement Other: Open heart surgery
TCD count of microembolic signals during surgical aortic valve replacement

Detailed Description:

Patients and clinical procedures 10 patients scheduled for open aortic valve surgery at our institution will be included into this prospective, observational study. The Human Ethics Committee of the University of Gothenburg, approved the study protocol. The day before surgery a lumbar puncture at level L3-4 will be performed using a 27G Whitacre needle. A sample of 2.5 ml of cerebrospinal fluid will be taken for analysis of S-100B, NSE, Tau and albumin.

On arrival at OR, standard perioperative monitoring will be established, including an Auditory Evoked Potential (AEP) monitor for anaesthetic depth measurements (AEP Monitor/2, Danmeter, Odense, Denmark) and radial arterial and central venous lines. General anaesthesia is induced with propofol 0.5-1 mg/kg and fentanyl 10 μg/kg. Tracheal intubation will be facilitated using atracurium 0,5 mg/kg. Sevoflurane is used to maintain an anaesthetic depth adjusted to an AAI index of 15-30 as recorded by the AEP monitor. Hemodynamic stability will be obtained by the use of colloidal solution administration, guided by the use of intra-operative transesophageal echocardiography, and norephineprine to maintain a mean arterial pressure above 75 mmHg-Also during CPB. A lumbar puncture will be repeated the first postoperative day repeating the measurement of markers in CSF A certified cardiologist or anaesthesiologist assess focal neurological impairment before and within 24 hours after the procedure.

Transcranial Doppler (TCD) By TCD the right medial cerebral artery (RMCA) will be insonated by the transtemporal approach at a depth of approximately 50 mm using standard criteria. The investigators use a 2 MHz power M-mode TCD monitor (ST3 ©, Spencer Technologies Seattle, WA), with the probe fixed in position using a head frame. The Doppler signals will be continuously monitored and saved to monitor hard drive. Two physicians independently evaluate the TCD data files offline, and identify microembolic signals (MES) using criteria for counting emboli signals on spectral and PMD TCD.

Statistical Analysis: Descriptive statistics and tests of normality for continuos data Correlation analysis; Total cerebral embolic load vs. increase of CSF level S-100B/ NSE/Tau.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Elective surgical aortic valve replacement

Criteria

Inclusion Criteria:

  • Clinical diagnosis aortic stenosis eligible for surgical treatment

Exclusion Criteria:

  • Coagulopathy
  • Regular Anticoagulation therapy
  • Carotid stenosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01319799

Locations
Sweden
Department of Thoracic Anaesthesia & Intensive Care,Sahlgrenska University Hospital
Gothenburg, Sweden, 41345
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
Investigators
Study Director: Sven Erik Ricksten, Professor Sahlgrenska University Hospital,Thoracic Anesthesia & Intensive Care
  More Information

Publications:
Responsible Party: Professor Sven Erik Ricksten, Sahlgrenska University Hospital. The sahlgrenska Academy.Institution Of Thoracic Anaesthesia & Intensive Care,Gothenburg Sweden
ClinicalTrials.gov Identifier: NCT01319799     History of Changes
Other Study ID Numbers: Dnr112-09
Study First Received: March 21, 2011
Last Updated: July 19, 2011
Health Authority: Sweden: The National Board of Health and Welfare

Keywords provided by Sahlgrenska University Hospital, Sweden:
Embolism
Nervous system
Aorta
Valves
Ultrasonics

Additional relevant MeSH terms:
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction

ClinicalTrials.gov processed this record on July 29, 2014